The new role of riluzole in the treatment of pancreatic cancer through the apoptosis and autophagy pathways

J Cell Biochem. 2021 Sep;122(9):934-944. doi: 10.1002/jcb.29533. Epub 2019 Nov 11.

Abstract

Pancreatic cancer is always diagnosed at an advanced stage. Hence, chemotherapy becomes the best choice for patients. Therefore, new anticancer drugs for pancreatic cancer are needed. Riluzole (RIL) is mainly used to treat amyotrophic lateral sclerosis clinically, but many previous studies have shown that RIL could inhibit tumors. However, no report has explored the association between RIL and pancreatic cancer. To validate this association, we performed this study. Our data showed that RIL could induce cytotoxicity, block the cell cycle, and inhibit clone formation, apoptosis, and migration in pancreatic cancer cells. Moreover, we demonstrated that RIL could suppress autophagy. However, more experiments will be needed to validate the reliability of our conclusions. In summary, our data suggest that RIL might provide clues for the development of a treatment for human pancreatic cancer in the future.

Keywords: apoptosis; autophagy; chemotherapy; pancreatic cancer; riluzole.

MeSH terms

  • Amyotrophic Lateral Sclerosis*
  • Apoptosis
  • Autophagy
  • Cell Line, Tumor
  • Humans
  • Pancreatic Neoplasms* / metabolism
  • Reproducibility of Results
  • Riluzole / pharmacology
  • Riluzole / therapeutic use

Substances

  • Riluzole